Please login to the form below

Not currently logged in
Email:
Password:

Hookipa Biotech appoints new global head of research and development

Dr Igor Matushansky joins the firm from Daiichi Sankyo

Dr Igor Matushansky

Hookipa Biotech has appointed Dr Igor Matushansky as its global head, research and development in a role that focuses on strategic priorities.

Previously global head of translational development for oncology at Daiichi Sankyo, Matushansky has experience in early oncology therapeutic programmes, strategy and development.

He said: “It’s an exciting time to join the Hookipa team and I am very eager to share my experience in drug development to further its mission to help patients.”

Matushansky has also previously worked for Novartis’ oncology translational medicine unit as clinical programme lead.

Joern Aldag, CEO at Hookipa Biotech, said: “Dr Matushansky’s valuable experience heading up R&D units at big pharma companies coupled with his significant immuno-oncology expertise will be transformative to Hookipa as we expand our company from prophylactic to therapeutic immuno-oncology focused therapies.

“I look forward to working together to achieve our goals and strategic priorities for 2017 and beyond.”

22nd March 2017

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
bmore group

OUR PROMISE: BETTER HEALTH FROM TRIAL TO TREATMENT.We are a full service, independent network of specialist agencies under one roof....

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics